Particle.news
Download on the App Store

AbbVie, Genentech Join TrumpRx With Deep Discounts on Humira and Xofluza

The move advances the White House plan to cut cash prices through most‑favored‑nation deals aimed at people without insurance.

Overview

  • AbbVie and Genentech, which joined Monday, become the 10th and 11th companies to sell through the White House’s TrumpRx portal.
  • Humira is listed at $950 for uninsured patients, an 86% cut from list prices that can top $6,900, and Genentech’s Xofluza is about $50 instead of $168.
  • The portal now features discounted cash prices for about 61 medications, up from roughly 40 at the February launch, with Amgen adding Enbrel and Otezla.
  • The discounts apply only to people paying the full price out of pocket, so many insured patients may still owe less through their plan copays than the site’s cash price.
  • The administration is using most‑favored‑nation agreements that peg U.S. cash prices to those in other countries, and officials say they want to extend these deals to public programs.